InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience

The term “In vivo” originates from Latin, meaning “within a living organism.” In the fields of life sciences and medicine, it describes experiments or processes conducted within a living organism. These in vivo antibodies target specific disease-related antigens and are used for the treatment or study of cancer, autoimmune diseases, and infectious diseases. In vivo antibodies regulate disease mechanisms by specifically binding to antigens involved in pathological processes or deliver drugs or radioisotopes precisely to target cells through antibody-drug conjugate (ADC) technology, thereby enhancing efficacy while minimizing damage to normal tissues.

abinScience boasts an extensive In Vivo antibody library, covering over 400 high-quality antibodies specifically designed for in vivo research. All antibodies undergo rigorous validation to ensure high purity, specificity, and functionality, making them widely applicable in disease mechanism studies, immunoassays, and drug development. We offer quantities ranging from milligrams to grams, with ready-to-ship inventory and fast delivery to meet diverse research needs. In animal model studies involving mice, non-human primates, and other species, antibodies serve not only as essential labeling tools but also as key regulators of the immune system.

Traditional hybridoma antibodies often lead to unstable experimental results in mouse models due to Fc fragment heterogeneity, high endotoxin levels, and batch-to-batch variability, particularly in tumor research and immune checkpoint analysis. Compared to conventional antibodies, abinScience’s InVivo Plus series of mouse in vivo antibodies offers significant advantages:

• ■Reduced immunogenicity: Does not induce neutralizing antibodies in the host, prolonging survival time in mice, improving experimental consistency and efficiency, and reducing antibody dosage.
• ■High batch-to-batch consistency: Ensures experimental reproducibility.
• ■High purity: Purity >98%.
• ■Ultra-low endotoxin levels: ≤1 EU/mg.
• ■Customized antibody formats: Designed for common applications, compatible with ELISA, FCM, and other in vitro experiments.
• ■Free of stabilizers, preservatives, and carrier proteins.

InVivoMAb™ Plus Anti-PD-1 and Anti-PD-L1 Antibody Activity Validation Experiments

The abinScience team conducted in vivo validation experiments on the InVivo Plus series antibodies. Below are the results for two key products:

1. InVivo Plus Anti-Mouse PD-1 Antibody (29F.1A12) (Catalog No.: MS870209) & InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) (Catalog No.: MS870039)

• ■Model Type: C57BL/6 mice inoculated with the B16-F10 melanoma model
• ■Experimental Method: Intraperitoneal injection of anti-PD-1 antibodies at predetermined doses
• ■Results:
  • Tumor growth curves show a dose-dependent suppression effect, significantly outperforming the control group

Figure 1: Anti-tumor effect of InVivo Plus Anti-PD-1 antibodies in the B16-F10 mouse melanoma model

2. InVivo Plus Anti-Mouse PD-L1 Antibody (10F.9G2) (Catalog No.: MV974029)

• ■Model Type: BALB/c mice inoculated with the CT26 colon cancer model
• ■Experimental Method: Intraperitoneal injection of anti-PD-L1 antibodies at predetermined doses
• ■Results:
  • InVivo Plus Anti-PD-L1 antibody (10F.9G2) significantly suppresses tumor growth in the CT26 model, demonstrating excellent in vivo anti-tumor activity.

Figure 2: Anti-tumor effect of InVivo Plus Anti-PD-L1 antibody in the CT26 mouse colon cancer model

InVivoMAb™ Plus Anti-PD-1 and Anti-PD-L1 Antibody ELISA Validation

To further validate the specificity and binding capacity of the antibodies, the abinScience team conducted ELISA tests on the InVivo Plus series antibodies. Below are the results for two products:

1. InVivo Plus Anti-Mouse PD-1 Antibody (29F.1A12) (Catalog No.: MS870209)

• ■Test Method: ELISA detection of the antibody’s binding affinity to mouse PD-1 antigen
• ■Results: The antibody exhibits high specificity in binding, with OD values significantly higher than the control group, indicating excellent antigen recognition capability

Figure 3: InVivo Plus Anti-PD-1 antibody ELISA test results, demonstrating its high specificity in binding

2. InVivo Plus Anti-Mouse PD-L1 Antibody (10F.9G2) (Catalog No.: MV974029)

• ■Test Method: ELISA detection of the antibody’s binding affinity to mouse PD-L1 antigen
• ■Results: The antibody shows strong binding to the PD-L1 antigen, with stable test results, making it suitable for both in vitro and in vivo studies

Figure 4: InVivo Plus Anti-PD-L1 antibody ELISA test results, demonstrating its stable antigen-binding capability

The above in vivo experiments and ELISA validations collectively demonstrate the stability, specificity, and functionality of abinScience’s InVivo Plus series antibodies, making them an ideal choice for tumor immunology, immune checkpoint research, and drug development. Classic clones such as PD-1/PD-L1 pathway antibodies (10F9G2, RMP1-14, D12) support tumor immunology studies; functional blocking antibodies (e.g., IFN-γ (XMG1.2), CD16/CD32 (2.4G2)) reduce non-specific binding; cytokine antibodies (e.g., IL-2 (JES6-1A12), CD40 (FGK45)) facilitate signaling studies; and T-cell activation antibodies (e.g., CD3 (UCHT-1), CD25 (PC61)) are used for regulatory T-cell research. For more products, click here to view.

InVivoMAb™ Plus Antibody Product List

Below is the abinScience InVivoMAb™ Plus series of antibodies and isotype controls, designed specifically for animal experiments, supporting immune regulation, tumor immunotherapy, and immune checkpoint research. Click on the catalog number for details:

Frequently Asked Questions About In Vivo Antibodies

How to choose in vivo antibodies suitable for animal experiments? Prioritize products with low endotoxin levels (≤1 EU/mg), high purity (>95%), and batch consistency, such as abinScience’s InVivoMAb™ Plus series.

Why are in vivo antibodies suitable for reproducible experiments? They are free of pathogens, have low endotoxin levels, and contain no preservatives, ensuring consistent results across multiple dosing experiments.

Can in vivo antibodies be used in tumor models? Yes, particularly anti-PD-1 and CTLA-4 antibodies, which perform exceptionally in tumor immune checkpoint studies, as demonstrated in the experiments.

High-Quality In Vivo Antibodies Drive Research Breakthroughs

Whether for basic research or drug development, abinScience InVivo MAbs provide robust support for studies on cancer, autoimmune diseases, and infectious diseases. Their batch stability, functional validation, and traceability form the foundation for reliable experiments. Visit the InVivoMAb™ Plus series to experience precise and reproducible animal experiment solutions.